ERBB2 and breast carcinoma: Negative HR status was associated with worse survival in one study.[25] HER-2 positive breast cancer treated with trastuzumab was found to have a longer time to LM compared to HER-2 positive non-trastuzumab treated individuals (15.2 versus 9.9 months; p = 0.008).